盐酸非索非那定片联合布地奈德鼻喷雾剂治疗中-重度变应性鼻炎的临床观察

目的观察盐酸非索非那定片联合布地奈德鼻喷雾剂治疗中-重度变应性鼻炎的疗效及安全性。方法选取2010年1月至2011年12月在解放军第九十二医院耳鼻咽喉科治疗的变应性鼻炎患者180例,按入院顺序分为三组,分别给予盐酸非索非那定片、布地奈德鼻喷雾剂以及联合治疗,观察治疗前后患者症状、体征评分,免疫球蛋白E水平,鼻分泌物中炎性细胞RNA/DNA比值以及不良反应发生率。结果三组患者治疗前以及治疗后第7、14、28日症状和体征评分,不同组间、不同时间点、组间·不同时间点的比较差异均有统计学意义(P<0.05);三组患者治疗后第7、14日疗效比较均有统计学意义(P<0.05);联合治疗组患者血清免疫球蛋白E水平、嗜酸性粒细胞、中性粒细胞RNA/DNA比值均显著低于其余两组;三组患者均未见严重不良反应,不良反应发生率比较无统计学意义(P>0.05)。结论盐酸非索非那定片联合布地奈德鼻喷雾剂治疗中-重度变应性鼻炎较单独使用更有效,且无严重不良反应。

Clinical Observation of Fexofenadine Hydrochloride Combined with Budesonide Nasal Spray as Treatment for Moderate-severe Allergic Rhinitis

Objective To observe the efficacy and security of fexofenadine hydrochloride combined with budesonide nasal spray treating moderate-severe allergic rhinitis. Methods A total of 180 patients from Otolaryngology Department of PLA 92^nd Hospital during Jan. 2010 and Dec. 2011 were selected and divided into 3 groups according to the order of admission, and fexofenadine hydrochloride, budesonide nasal spray and combined therapies were given respectively. The symptoms and signs scores, IgE levels, RNA/DNA ratio of inflammatory ceils in nasal secretions before and after treatment and adverse reaction rate were observed. Results The symptoms and signs scores before treatment and 7,14,28 days after treatment of three groups were significantly different, the difference of different groups, different times and groups ~ times were statisti- cally significant （P 〈 0. 05 ）. The curative effect of the 3 groups were different after treatment for 7 and 14 days（P 〈0.05）. The serum IgE levels, RNA/DNA ratio of eosnophils and neutrophils of combined therpay group were significantly lower than the other two groups. No serious adverse reactions were observed in all of the three groups and the difference of adverse reactions incidence had no statistical significance（ P 〉 0.05 ）. Conclusion Fexofenadine hydrochloride combined with budesonide nasal spray is more effective in treating moderate-severe allergic rhinitis than single application and has no serious adverse actions.